Key result
Novel antihypertensive drugs and renal denervation offer new options for blood pressure control.
Why the study?
Racially and ethnically diverse populations in the United States experience a disproportionate burden of hypertension, prompting a need to evaluate the evidence for new and investigational drug and device therapies in these groups.
Do recently approved and investigational antihypertensive drugs and device-based interventions improve hypertension control and reduce cardiovascular risk in racially and ethnically diverse populations?
Do recently approved and investigational antihypertensive drugs and device-based interventions improve hypertension control and reduce cardiovascular risk in racially and ethnically diverse populations?
Novel antihypertensive drugs (such as baxdrostat, lorundrostat, finerenone, and aprocitentan) and renal denervation offer potential to improve blood pressure control beyond the 2025 AHA/ACC guidelines, though equitable representation in clinical trials and delivery across diverse populations remains critical.
Answers are grounded in this paper and cite their sources.
Targeted enrollment in hypertension trials is essential for equitable benefit; extends 2025 AHA/ACC guidelines by identifying representation gaps in novel agents.
Purpose of Review Hypertension is the leading modifiable cardiovascular risk factor in the United States, with racially/ethnically diverse populations experiencing a disproportionate burden, associated with social, structural, and potentially biological determinants. This review examines how recently approved and investigational pharmacologic therapies and device-based interventions may advance hypertension control in 2026 and beyond, with deliberate attention to the strength and applicability of the available evidence in racially/ ethnically diverse populations. Recent Findings Aldosterone synthesis and mineralocorticoid receptor signaling represent important advances beyond the present guidelines for resistant hypertension and cardiovascular-kidney-metabolic risk reduction. For instance, baxdrostat, a recently approved aldosterone synthase inhibitor (ASI), has demonstrated clinically meaningful blood pressure reductions. In addition, lorundrostat, an investigational ASI, provides a model for racially representative trial design through the intentional enrollment of Black and Hispanic/Latino participants and consistent efficacy across racial subgroups. In contrast, pivotal finerenone trials demonstrated improved cardiac and renal outcomes but included limited representation of Black adults. Additional approved therapies include an agent targeting the endothelin pathway, aprocitentan, and device-based interventions via renal denervation therapy, although their effectiveness in diverse populations remains unknown. Therapies targeting natriuretic peptide signaling remain investigational but could potentially expand the therapeutic landscape. Summary Advances in antihypertensive therapy offer new opportunities to improve blood pressure control and reduce cardiovascular risk beyond the 2025 American Heart Association (AHA) and American College of Cardiology (ACC) AHA/ACC High Blood Pressure Guideline-directed approach. Ensuring equitable benefit from these innovations requires that therapeutic innovation be coupled with deliberate efforts to ensure equitable delivery and benefit across populations.
No takes yet. Share an insight, caveat, or question.
Odo et al. (2026) conducted a review in Hypertension. Recently approved and investigational antihypertensive drugs and devices (e.g., baxdrostat, lorundrostat, finerenone, aprocitentan, renal denervation) was evaluated on Blood pressure control and cardiovascular-kidney-metabolic risk reduction. Novel antihypertensive therapies (e.g., baxdrostat, lorundrostat, aprocitentan, renal denervation) offer new opportunities for blood pressure control beyond 2025 AHA/ACC guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: